Article
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
Molecular cancer - 3 May 2011
Tovar Christian, Higgins Brian, Kolinsky Kenneth, Xia Mingxuan, Packman Kathryn, Heimbrook David C, Vassilev Lyubomir T
Abstract excerpt
BACKGROUND: Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major pathway that can block cell proliferation or induce apoptosis in response to diverse forms of oncogenic stress. Activation of the p53 pathway in cancer cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.